Treatments are available for dry AMD patients who also have geographic atrophy, but until the FDA's recent authorization of light therapy, those with dry AMD alone had no treatment options other than ...

PARIS, Sept. 04, 2025 (GLOBE NEWSWIRE) -- PulseSight Therapeutics, an ophthalmology biotech company developing disruptive non-viral vectorized therapies with minimally-invasive delivery technology ...

Age-Related Macular Degeneration (AMD) is the biggest cause of sight loss in the UK, affecting around 700,000 people. As ...

The FDA issued a third complete response letter for ONS-5010/Lytenava, requesting confirmatory efficacy evidence for wet AMD treatment. Lytenava is an ophthalmic bevacizumab formulation, potentially ...

– In AVONELLE-X, the largest long-term extension trial in wet AMD, disease control and durability were maintained over 4 years, with nearly 80% of patients on extended dosing by study end – – Over 60% ...

A laser treatment for this common eye disease will start clinical trials in Finland next spring ––researchers hope it could be available to sufferers in as little as three years Around a third of ...

Please provide your email address to receive an email when new articles are posted on . GLP-1 drugs were linked to significantly lower risk for age-related cataracts. They were also tied to reduced ...

There is strong interest across many stakeholders to increase progress around developing treatments for dry age-related macular degeneration (AMD). Advancements in drug discovery and development in ...